Developing Rapid-Acting Treatments for Neuropsychiatric Diseases

See latest data
Our Focus

TSND-201
a rapid-acting neuroplastogen
for PTSD

We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. 
Learn More
News

The Latest From Transcend

Otsuka Pharmaceutical to Acquire Transcend Therapeutics Read More
Press Release

Otsuka Pharmaceutical to Acquire Transcend Therapeutics
IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD Read More
Press Release

IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD
New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology Read More
Press Release

New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology
Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND- 201 (methylone) for the Treatment of PTSD Read More
Press Release

Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND- 201 (methylone) for the Treatment of PTSD
Learn More
Our Mission

Striving for a world without neuropsychiatric disease.

Because 1 billion patients
deserve better.
Careers

Help us bring new mental health solutions to patients

Join us in creating a world free from neuropsychiatric disease.
Learn More